{Reference Type}: Journal Article
{Title}: NDC80/HEC1 promotes macrophage polarization and predicts glioma prognosis via single-cell RNA-seq and in vitro experiment.
{Author}: Ye W;Liang X;Chen G;Chen Q;Zhang H;Zhang N;Huang Y;Cheng Q;Chen X;
{Journal}: CNS Neurosci Ther
{Volume}: 30
{Issue}: 7
{Year}: 2024 Jul
{Factor}: 7.035
{DOI}: 10.1111/cns.14850
{Abstract}: <B>BACKGROUND: </B>Glioma is the most frequent and lethal form of primary brain tumor. The molecular mechanism of oncogenesis and progression of glioma still remains unclear, rendering the therapeutic effect of conventional radiotherapy, chemotherapy, and surgical resection insufficient. In this study, we sought to explore the function of HEC1 (highly expressed in cancer 1) in glioma; a component of the NDC80 complex in glioma is crucial in the regulation of kinetochore.<BR><B>METHODS: </B>Bulk RNA and scRNA-seq analyses were used to infer HEC1 function, and in vitro experiments validated its function.<BR><B>RESULTS: </B>HEC1 overexpression was observed in glioma and was indicative of poor prognosis and malignant clinical features, which was confirmed in human glioma tissues. High HEC1 expression was correlated with more active cell cycle, DNA-associated activities, and the formation of immunosuppressive tumor microenvironment, including interaction with immune cells, and correlated strongly with infiltrating immune cells and enhanced expression of immune checkpoints. In vitro experiments and RNA-seq further confirmed the role of HEC1 in promoting cell proliferation, and the expression of DNA replication and repair pathways in glioma. Coculture assay confirmed that HEC1 promotes microglial migration and the transformation of M1 phenotype macrophage to M2 phenotype.<BR><B>CONCLUSIONS: </B>Altogether, these findings demonstrate that HEC1 may be a potential prognostic marker and an immunotherapeutic target in glioma.